Lab Relief
Executive Summary
Reference laboratories, which have suffered for most of the past decade from ever-declining reimbursement rates, had a welcome piece of good news this year--as of Jan. 1, Medicare reimbursement for many anatomic pathology processes is slated to increase. The increases vary by procedure, but some of the biggest categories--biopsies, for example--will rise by as much as 33% over the next three years. Reimbursement for Pap smears is doubling, although Medicare is responsible for only a small portion of pap smears. The reimbursement hike caused Dianon to restate its revenue projections for this fiscal year from a 30% increase to a 40% increase.
You may also be interested in...
Impath's Informatics Play
Impath's unorthodox step into the cancer information business has made it attractive to Wall Street, but will its vast, specialized databases allow it to reap benefits from pharmacogenetics? The real value to Impath of its databases resides in their ability to promote work on targeted therapeutics, whose use in patients will depend on critical markers. But targeted therapeutics are a controversial concept that requires pharma companies to make basic changes in the way they operate. There's no guarantee Impath can get the pay-off it wants from its new initiatives.
Eisai Plots A Meticulous Path To CMS Coverage For Lecanemab
The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab.
Symptoms Change But Savings OTC Drugs Deliver For US Health Care Spending Continue Growing
Substantially more consumers in 2022 report sleep issues, allergies and skin problems than in 2018 while using quit smoking aids has dropped, according to CHPA’s latest “Value of OTC Medicines” survey. Average annual household spending on OTCs is $645.